Apr 23 |
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
|
Apr 18 |
BiomX Announces the Appointment of Susan Blum to its Board of Directors
|
Apr 5 |
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
|
Apr 4 |
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
|
Apr 3 |
BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript
|
Apr 3 |
BiomX GAAP EPS of -$0.51
|
Apr 3 |
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|